Safer Opioids: Separating Pain Relieving Properties from Dangerous Side Effects
Opioid drugs are the most widely prescribed and effective type of pain medication. But they are highly addictive and have some unpleasant and potentially deadly side effects.
Now a group of researchers, led by Dr. Laura Bohn at The Scripps Research Institute, may have found a way to make opioids safer by separating the drugs' pain relieving effects from their most dangerous side effect, respiratory suppression, which, in very severe cases, causes patients to stop breathing and to die.
All opioid drugs elicit their effects via a small group of protein receptors, called opioid receptors. When an opioid drug binds to its receptor, the receptor is activated and kicks off a chain of reactions that relieve pain. However, the activated opioid receptor can also interact with other nearby signaling proteins, causing side effects such as nausea, sedation, constipation or, most seriously, respiratory suppression.
Dr. Bohn's team has identified several molecules considered to be "biased agonists" because they act at the opioid receptor to stimulate pain relief, but cause less stimulation of the pathway that leads to respiratory suppression. In preliminary studies using mice, the researchers found that the most promising of these compounds provided pain relief levels similar to morphine, but with significantly less respiratory suppression.
Such opioids could help patients and doctors deal with drug tolerance, a frequent complication in which, over time, patients lose sensitivity to the pain-blocking properties of opioids and require higher doses to treat their pain. While biased agonists may be able to be used more safely at higher doses than other opioids, it remains to be seen how other side effect profiles will be affected.
One compound identified as a biased agonist--from the company Trevena--is already showing promising results as it makes its way through clinical trials, and the researchers hope that new compounds with stronger biases will yield even better results.
The recent epidemic of opioid-related deaths has been driven primarily by use of illegally made opioid drugs. However, prescription opioids are playing a significant role in the epidemic. As opioid overdose deaths are mostly due to respiratory suppression, safer prescription opioids, such as those being developed by Dr. Bohn, could also ultimately decrease the number of deaths caused by abusing prescription opioids.
This article has been republished from materials provided by American College of Neuropsychopharmacology. Note: material may have been edited for length and content. For further information, please contact the cited source.
Cryo-EM Reveals Interaction Between Major Drug TargetsNews
For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Novel Microplate 3D Bioprinting Platform for Engineering Muscle and Tendon TissuesNews
There is a strong need for medication that treats age-related degenerative muscle and tendon diseases. A critical bottleneck in the discovery and development of novel drugs for skeletal muscle is the lack of efficient and robust functional in vitro assays for compound screening. Researchers describe the development of a novel screening platform with automated production of 3D muscle- and tendon–like tissues using 3D bioprinting.READ MORE